Cryolife Files Form 10-Q For First Quarter 2004
May 13 2004 - 4:10PM
PR Newswire (US)
Cryolife Files Form 10-Q For First Quarter 2004 ATLANTA, May 13
/PRNewswire-FirstCall/ -- CryoLife, Inc. , a bio-surgical device
and human tissue processing company, announced today that it has
addressed with the Securities and Exchange Commission ("SEC") its
accounting for product liability claims and filed its Form 10-Q for
the first quarter. Founded in 1984, CryoLife, Inc. is a leader in
the processing and distribution of implantable living human tissues
for use in cardiovascular and vascular surgeries throughout the
United States and Canada. The Company's BioGlue(R) Surgical
Adhesive is FDA approved as an adjunct to sutures and staples for
use in adult patients in open surgical repair of large vessels and
is CE marked in the European Community and approved in Canada for
use in soft tissue repair and approved in Australia for use in
vascular and pulmonary sealing and repair. The Company also
manufactures the SG Model #100 Vascular Graft, which is CE marked
for distribution within the European Community. For additional
information about the company, visit CryoLife's Web site:
http://www.cryolife.com/ Contact: D. Ashley Lee Vice President and
CFO (770) 419-3355 DATASOURCE: CryoLife, Inc. CONTACT: D. Ashley
Lee, Vice President and CFO of CryoLife, Inc., +1-770-419-3355 Web
site: http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024